Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Bought by Sei Investments Co.

Sei Investments Co. grew its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 14.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 116,318 shares of the biopharmaceutical company’s stock after purchasing an additional 14,849 shares during the period. Sei Investments Co. owned approximately 0.10% of Catalyst Pharmaceuticals worth $2,428,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of CPRX. abrdn plc acquired a new position in Catalyst Pharmaceuticals during the fourth quarter valued at approximately $10,115,000. Raymond James Financial Inc. purchased a new stake in Catalyst Pharmaceuticals during the 4th quarter worth $6,887,000. Skandinaviska Enskilda Banken AB publ raised its position in Catalyst Pharmaceuticals by 74.3% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 731,900 shares of the biopharmaceutical company’s stock valued at $15,421,000 after purchasing an additional 312,000 shares during the period. Jane Street Group LLC lifted its stake in shares of Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after purchasing an additional 285,564 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its position in shares of Catalyst Pharmaceuticals by 5.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after buying an additional 151,495 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Brian Elsbernd sold 62,975 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on CPRX. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 28th. Stephens reaffirmed an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Monday, February 3rd. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Finally, Robert W. Baird upped their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $32.29.

Catalyst Pharmaceuticals Trading Down 4.3 %

Shares of CPRX opened at $23.07 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $26.16. The firm has a market cap of $2.80 billion, a price-to-earnings ratio of 19.55, a PEG ratio of 3.31 and a beta of 0.79. The stock has a 50 day moving average of $22.78 and a 200-day moving average of $21.94.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.